PEeR Exchange® Assessing Racial and Ethnic Disparities in Lung Cancer Care

Release Date: December 23, 2021
Expiration Date: December 23, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from Merck & Co., Inc. and Novartis Pharmaceuticals Corporation.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify strategies to overcome racial disparities in diagnosis, testing, and treatment for patients with lung cancer.
• Outline racial disparities in outcomes for patients with early-stage or advanced non–small cell lung cancer (NSCLC).
• Review the incidence of NSCLC in different racial, ethnic, and socioeconomic groups.
• Determine the implications of emerging treatments in the management of patients with advanced NSCLC across racial, ethnic, and socioeconomic backgrounds.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
 

Chair

Narjust Duma, MD
Assistant Professor of Medicine
Thoracic Oncologist
Dana-Farber Cancer Institute
Boston, MA

Debora Bruno, MD, MS
Assistant Professor of Medicine
Case Western Reserve University
Division of Hematology and Medical Oncology
Co-Chair, Committee on Disparities in Clinical Research
Case Comprehensive Cancer Center/University Hospitals
Cleveland, OH

Disclosures: Debora Bruno, MD, MS, has no relevant financial relationships with ineligible companies.

Estelamari Rodriguez, MD, MPH
Co-Lead, Thoracic Site Disease Group
Associate Director for Community Outreach
Voluntary Assistant Professor of Clinical Medicine
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Aventura, FL

Disclosures: Consultant: Roche.
 
PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.